Freenome Announces Expanded Artificial Intelligence and Deep Learning Initiatives Accelerated by NVIDIA, to Advance Personalized Multi-Cancer Detection
Publish Date: 2026-01-12 10:00:00
Source Domain: www.prnewswire.com
-
Collaboration to Enhance Early Cancer Screening: Freenome announced a partnership with NVIDIA to leverage deep learning technology to improve its blood-based early cancer screening tests, especially in recognizing subtle cancer signals at the earliest stages.
-
NVIDIA’s Accelerated Computing to Improve Data Processing: The collaboration aims to use NVIDIA’s advanced computing capabilities to overcome bottlenecks in training and scaling Freenome’s fragment-level deep learning (FLDL) models for analyzing massive cfDNA datasets.
-
Open-Source Foundation Model Development: Freenome will develop a foundation model that contextualizes cfDNA methylation patterns using the NVIDIA BioNeMo Framework, aiming to make it available to the broader research community for multiple applications beyond cancer detection.
-
Enhancing Healthcare Organizations’ AI Research: Freenome is working with NVIDIA to provide healthcare organizations with tools that can quickly process large clinical and molecular datasets, thus supporting research into potential new diagnostics and prognostic tools.
-
Upcoming FDA Review and New Test Launches: SimpleScreen™ CRC, Freenome’s test for colorectal cancer, is under review by the FDA, expected for approval in the second half of 2026. Additionally, Freenome plans to launch several other blood-based cancer detection tests, targeting lung cancer and more, in the year 2026.
